Abbvie Inc
NYSE: ABBV
$193.46
-$0.16 (-0.1%)
Real Time Data Delayed 15 Min.
ABBV Articles
With billions of dollars flowing in, it has become impossible to ignore the ESG trend. These 15 top ESG stocks appear to be undervalued against the performance of the broader markets.
Published:
With even moderate appreciation in the share prices of these top companies, investors should be looking at double-digit total return potential. In a market that is very long in the tooth, that makes...
Published:
Tuesday's top analyst upgrades, downgrades and initiations included AbbVie, Apple, Arconic, CenturyLink, eHealth, Nvidia, Salesforce.com, Tesla and Teva Pharmaceutical.
Published:
The January 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Monday's top analyst upgrades, downgrades and initiations included AbbVie, Apple, Arch Coal, FedEx, Ford, General Motors, Nvidia, Skyworks Solutions, Stitch Fix and World Wrestling Entertainment.
Published:
AbbVie released better than expected fourth-quarter financial results before the markets opened on Friday.
Published:
Thursday's top analyst upgrades, downgrades and initiations included AbbVie, Biogen, Boeing, Etsy, Gilead Sciences, GoPro, Micron Technology, Newmont, Peloton Interactive, Pfizer, Valero Energy and...
Published:
The January 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
These five stock income ideas are rated Buy by major Wall Street firms and offer consistent and dependable dividends. They are good choices for income-seeking investors with a higher risk tolerance.
Published:
24/7 Wall St. has put together a preview of AbbVie, American Airlines, Netflix, Starbucks and some of the other most prominent earnings reports due in this truncated trading week.
Published:
The December 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
The December 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
The FDA has approved Allergan's treatment for migraines in adults. The drug is the first of its class to obtain FDA approval, but the new drug will compete with other recently released treatments for...
Published:
The November 29 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
The November 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published: